These Analysts Lower Their Forecasts On Mastercard After Q3 Earnings

Mastercard Inc (NYSE: MA) reported better-than-expected earnings for its third quarter.

Mastercard Inc (NYSE:MA) reported better-than-expected earnings for its third quarter.

Net revenues stood at $6.53 billion, up 14% Y/Y and 11% Y/Y on a neutral currency basis, beating the consensus of $6.52 billion. Adjusted EPS rose 26% Y/Y to $3.39, exceeding the consensus of $3.21.

Mastercard shares slipped 0.01% to trade at $364.58 on Friday.

These analysts made changes to their price targets on Mastercard following earnings announcement.

  • Keybanc cut the price target on Mastercard from $440 to $430. Keybanc analyst Alex Markgraff maintained an Overweight rating.
  • Raymond James slashed the price target on Mastercard from $453 to $452. Raymond James analyst John Davis maintained an Outperform rating.
  • Morgan Stanley lowered the price target on Mastercard from $443 to $439. Morgan Stanley analyst James Faucette maintained an Overweight rating.
  • BMO Capital cut the price target on Mastercard from $488 to $472. BMO Capital analyst James Fotheringham maintained an Outperform rating.
  • RBC Capital cut the price target on Mastercard from $441 to $432. RBC Capital analyst Daniel Perlin maintained an Outperform rating.

Also Check This Out: Top 4 Industrial Stocks That May Plunge In Q4

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Evusheld Long-acting Antibody Combination Recommended for Approval in the EU for the Treatment of COVID-19

AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

AZN